Genetic and Genomic Factors Driving Prostate Cancer in American Men
Official title: Genetic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535331 · Data updated 2026-11-12
This grant looks at how inherited genes and tumor DNA affect the risk and behavior of prostate cancer in American men, with a focus on diverse populations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $53,769 |
| NIH project number | 3R01CA259200-05S7 |
| Project ID | NIH-11535331 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with prostate cancer or at risk due to family history, including diverse populations such as African ancestry groups.
✕Less likely to help
Results may be less directly applicable to men outside the studied populations or with very different genetic backgrounds.
What this research studies
Prostate cancer shows strong links to both inherited genetic factors and the tumor’s own DNA. The project plans to look across many genetic variants and tumor features to understand how they influence how likely cancer is to occur and how aggressive it may be. By studying DNA from patients and tumors, researchers aim to identify subtypes that respond differently to treatment. This work builds toward translating genetic findings into better, more personalized care for men with prostate cancer, including those of African descent.
Why it matters
Potential benefit: If successful, the work could improve risk assessment, diagnosis, and personalized treatment choices for prostate cancer.
How similar studies have gone: Prior research has identified many genetic variants associated with risk; this project aims to extend understanding to diversity and tumor biology to improve translation.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.